5
Participants
Start Date
November 9, 2023
Primary Completion Date
May 13, 2024
Study Completion Date
May 13, 2024
BMS-986466
Specified dose on specified days
Adagrasib
Specified dose on specified days
Cetuximab
Specified dose on specified days
Local Institution - 0053, Westmead
Local Institution - 0040, Athens
Local Institution - 0020, Lille
Local Institution - 0047, Los Angeles
Local Institution - 0082, Petah Tikva
Local Institution - 0081, Tel Aviv
Local Institution - 0025, Hackensack
Local Institution - 0008, Morristown
Local Institution - 0083, Helsinki
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY